ZYDUSWELL

- Trading window will remain closed from October 1, 2026. - Closure will last until 48 hours after the declaration of unaudited financial results for the quarter and half-year ending September 30, 2026. - Date of the Board meeting to approve the results will be informed in due course.

- Mr. Arijit Sengupta, Chief Marketing Officer and part of the Senior Management of Zydus Wellness Limited, has tendered his resignation effective from the close of business hours on September 18, 2026. His last working day will also be September 18, 2026.

- Zydus Wellness Limited responded to NSE's query regarding a significant spurt in its share volume. - The company clarified that all necessary disclosures have been made and there is no undisclosed material information impacting the price/volume behavior. - It believes the volume increase is purely market-driven, and the company has no control or knowledge of the reasons.

- Zydus Wellness received an updated ESG score of 71.7 from SES ESG Research Pvt. Ltd. on September 2, 2026. - This is an improvement from the 70 score for the Financial Year 2024-25.

- Concall Schedule - Concall Date: Tuesday, September 22, 2026 - Event: Anand Rathi G-200 Summit 2026 (Group and one-on-one meeting)

- Zydus Wellness Limited announced the appointment of Mr. Kapil Sharma as Chief Revenue Officer (India and Indian subcontinent). - The appointment is effective September 1, 2026. - Mr. Sharma brings over 28 years of experience, including 25 years at Procter & Gamble, to the senior management team.

- Disclosure under SEBI (PIT) Regulations, 2015, regarding the transmission of 27,250 equity shares from Late Jasodaben Babubhai Patel to Mr. Prashant Babubhai Patel, both members of the Promoter Group. - Date of intimation: August 21, 2026.

- Zydus Wellness Products Limited (ZWPL), a wholly-owned material subsidiary, received a 'CARE AA+; Stable' credit rating for its ₹12.00 crore long-term bank facilities from CARE Ratings Limited. - The Stable outlook reflects the Zydus Wellness Group's established market position and strong operational and financial support from its promoter group.

- Q1 FY27 Consolidated Net Sales grew 66.7% YoY to INR 14,299 million. - Q1 FY27 EBITDA grew 55.3% YoY to INR 2,417 million. - Reported Net Profit declined 7%; however, excluding amortization of acquired brands, net profit grew 26.5%. - International business delivered 24.8% like-to-like growth, while domestic business grew 4.6% led by Skin & Hair Care (34.5%) and Food & Nutrition (16%). - Seasonal brands declined 12% due to unseasonal summer, but management anticipates growth momentum to return in the coming quarters. - The company launched Complan Power Play milkshake and VieMax Diabetes Care, with a robust long-term innovation pipeline for the next 2-3 years. - Comfort Click business remains EPS accretive, and management expects continued margin improvement. - The effective tax rate for Q1 FY27 was ~27%, projected at 25% for FY27 (with a lower cash component initially), moving to a fully cash basis from next year.

- Zydus Wellness received an updated ESG rating from Crisil ESG Ratings & Analytics Ltd. - The company's ESG category has been upgraded from "Adequate" to "Strong." - The Crisil ESG rating increased from 59 (FY2025) to 66 (FY2026), with a fresh Crisil Core ESG rating of 70 for FY2026.

- Concall Schedule - Concall Date: Friday, August 14, 2026 - Conference Name: Equirus Annual India Conference 2026 - Hosted by: Equirus Securities - Type of Meeting: Group and one-on-one meeting

- The audio recording of the Investor Call on unaudited financial results for the quarter ended June 30, 2026, is available on the company's website. - The link to access the recording is provided.

- Shareholders at the 32nd AGM on August 4, 2026, approved the appointment of Mr. Apurva S. Diwanji as an Independent Director for a term of 5 years, effective May 18, 2026 to May 17, 2031.

- The 32nd Annual General Meeting of Zydus Wellness Limited was held on August 4, 2026. - All six resolutions were passed with the requisite majority. - Key resolutions passed include adoption of financial statements for FY26, re-appointment of Dr. Sharvil P. Patel as Non-Executive Director, appointment of Mr. Apurva S. Diwanji as Independent Director, ratification of Cost Auditors' remuneration, and declaration of a dividend of ₹1.20 per equity share for FY26.

- Consolidated Revenue ₹1,429.9 Cr vs ₹857.7 Cr (▲66.7% YoY) - EBITDA ₹241.7 Cr vs ₹155.6 Cr (▲55.3% YoY) - PAT ₹118.9 Cr - EBITDA Margin 16.9% vs 18.1% (▼120bps)

- Consolidated Revenue ₹14,370Mn vs ₹8,609Mn (▲67% YoY) - EBITDA ₹2,455Mn vs ₹1,586Mn (▲55% YoY) - PAT ₹1,189Mn vs ₹1,279Mn (▼7% YoY) - EBITDA Margin 17.1% vs 18.4% (▼130bps)